Physician profile
John Palermo
NPI 1033143995
$5,947.48
in general payments reported to CMS, 2019-2025
13 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $648 · 2022: $1,845 · 2023: $790 · 2024: $1,116 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,509.64 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Intra-Sana Laboratories | $1,065.96 | 2021-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $1,026.89 | 2021-2025 | |
| Novo Nordisk INC | $559.85 | 2021-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $453.27 | 2022-2024 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.37 | 2021-2022 | |
| Amgen INC. | $248.38 | 2023-2025 | Evenity |
| Merck Sharp & Dohme LLC | $173.05 | 2022-2025 | Capvaxive |
| Abbott Laboratories | $143.21 | 2022 | |
| Abbvie INC. | $127.63 | 2024 | |
| Glaxosmithkline, LLC. | $106.83 | 2022 | |
| Astellas Pharma US INC | $95.69 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $81.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Palermo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.